Coronavirus COVID-19 Updates: uc.edu/publichealth
Radiation therapy is a powerful, non-invasive tool for controlling primary and metastatic tumors in adults and children. However, radiotherapy has two primary limitations: 1) it has limited utility in controlling widely metastatic disease, and 2) it can
cause toxic late effects, especially in growing children. My laboratory is focused on addressing these two limitations of radiotherapy by studying the effects of ionizing radiation on the immune system.
There is evidence that the immune system plays an important role in radiation mediated tumor control, and under
rare circumstances radiation therapy can induce a systemic anti-tumor immune response resulting in an “abscopal” effect away from the radiation target. Radiation alone does not stimulate a strong immune response against tumors, however
when combined with immune modulating agents such as antagonists of CTLA-4 and PD1, radiation can stimulate specific, protective anti-tumor immunity. We aim to understand the mechanism of radiation induced anti-tumor immunity and resistance to tumor
specific cytotoxic T cells utilizing pre-clinical models and clinical trials. Currently, we are testing the use of focal radiotherapy to facilitate recruitment of adoptive cell based therapies using patient derived xenografts of pediatric sarcomas,
and we have an ongoing phase I clinical trial for pediatric and young adult patients with relapsed and refractory solid tumors and lymphoma testing the combination of a PD1 inhibitor (Pembrolizumab) to combat T-cell exhaustion, an epigenetic modifying
agent (decitabine) to increase expression of tumor associated antigens, and hypofractionated radiotherapy to induce immunogenic tumor cell death and modify the tumor microenvironment. (NCT03445858)
Radiation induced inflammation can be a double edged sword, and many of the toxic effects of radiotherapy are associated with and may be mediated by inflammation. Radiation necrosis of the brain is an example of a rare but morbid sub-acute toxicity experienced
by patients who receive radiotherapy for brain tumors. Radiation necrosis is associated with inflammation and death of normal brain cells, however it is unclear if radiation induced inflammation mediates necrosis of normal brain tissue, or if radiation
injures brain tissue, which then incites an inflammatory response. We aim to understand this mechanism in order to better understand which patients are most at risk for this toxic effect, and how radiation necrosis can be prevented.
There are many forms of ionizing radiation that can be used for cancer treatment. The two most common forms used for cancer treatment utilize collimated beams of high energy X-rays (photons) and high energy protons. Both are thought to be equally effective
at controlling tumors, however proton beams are increasingly used for treating pediatric patients due to the physical properties of protons which deposit the majority of their energy in a small volume at the end of range (Bragg peak). This allows
for relative sparing of normal tissues compared with photon beams which deposit increased dose in normal tissues proximal and distal to the tumor target. While clinical data demonstrate proton therapy is as safe and effective as photon therapy, the
physical interactions on the sub-cellular, molecular, and sub-atomic levels are fundamentally different, and there are likely different biological effects. Utilizing the dedicated research gantry at the Cincinnati Children’s Hospital Proton
Research Center and the Xenx research photon irradiator at the University of Cincinnati Vontz Center, we aim to understand these biological differences between protons and photons as they relate to radiation induced inflammation and immunity.
Vinita Takiar, MD, PhDDepartment of Radiation OncologyThe Barrett Cancer Center234 Goodman Street, ML 0757Cincinnati, OH 45267-0757Office: 513-584-1450Email: firstname.lastname@example.org
Trisha Wise-Draper, MD, PhDDepartment of Internal MedicineUniversity of Cincinnati College of Medicine231 Albert Sabin Way, MSB Room 6065Cincinnati, OH 45267-0557Office: 513-558-2826Email: email@example.com